相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2016)
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew et al.
BRITISH JOURNAL OF CANCER (2016)
Safety and efficacy results from a phase I dose -escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies
Zev A. Wainberg et al.
CANCER RESEARCH (2016)
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek et al.
GYNECOLOGIC ONCOLOGY (2016)
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J. Mateo et al.
TARGETED ONCOLOGY (2016)
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1-/- murine model of ovarian cancer
Jing Huang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients
Vasiliki Michalarea et al.
CANCER RESEARCH (2015)
Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort
Ursula A. Matulonis et al.
CANCER RESEARCH (2015)
Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies
Z. A. Wainberg et al.
EUROPEAN JOURNAL OF CANCER (2015)
DNA repair deficiencies in ovarian cancer: Genomic analysis of high grade serous ovarian tumors from the NOVA study
K. Timms et al.
EUROPEAN JOURNAL OF CANCER (2015)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Clare L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Mechanistic Dissection of PARP1 Trapping and the Impacton In Vivo Tolerability and Efficacy of PARP Inhibitors
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
J-m. Lee et al.
ANNALS OF ONCOLOGY (2014)
PARP inhibitors for anticancer therapy
Nicola Curtin
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
G. Del Conte et al.
BRITISH JOURNAL OF CANCER (2014)
New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances
Joyce Liu et al.
CLINICAL CANCER RESEARCH (2014)
Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib
E. Swisher et al.
EUROPEAN JOURNAL OF CANCER (2014)
Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer
P. Haluska et al.
EUROPEAN JOURNAL OF CANCER (2014)
Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
Julie K. Horton et al.
MOLECULAR CANCER RESEARCH (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu et al.
LANCET ONCOLOGY (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
New perspectives in ovarian cancer treatment
Bernd C. Schmid et al.
MATURITAS (2014)
Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining
Aashish Soni et al.
NUCLEIC ACIDS RESEARCH (2014)
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway
Chiara Gorrini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2
Ashok R. Venkitaraman
SCIENCE (2014)
PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
Yiduo Hu et al.
CANCER DISCOVERY (2014)
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Kirsten M. Timms et al.
BREAST CANCER RESEARCH (2014)
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Mo Li et al.
CANCER CELL (2013)
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Joo Ern Ang et al.
CLINICAL CANCER RESEARCH (2013)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
Rules of engagement for base excision repair in chromatin
Ian D. Odell et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
Chiara Gorrini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
Geoffrey Shapiro et al.
MOLECULAR CANCER THERAPEUTICS (2013)
RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
J. Ross Chapman et al.
MOLECULAR CELL (2013)
A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice
Cristina Escribano-Diaz et al.
MOLECULAR CELL (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection
Michal Zimmermann et al.
SCIENCE (2013)
Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
Michela Di Virgilio et al.
SCIENCE (2013)
Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Smita Bhatia
SEMINARS IN ONCOLOGY (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells
Silvana B. De Lorenzo et al.
FRONTIERS IN ONCOLOGY (2013)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
Tatiana Popova et al.
CANCER RESEARCH (2012)
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2012)
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Anand G. Patel et al.
CLINICAL CANCER RESEARCH (2012)
Towards a structural understanding of PARP1 activation and related signalling ADP-ribosyl-transferases
Markus Hassler et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2012)
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Kelly L. Bolton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Stan B. Kaye et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Quantitative Live Cell Imaging Reveals a Gradual Shift between DNA Repair Mechanisms and a Maximal Use of HR in Mid S Phase
Ketki Karanam et al.
MOLECULAR CELL (2012)
Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
J. Ross Chapman et al.
MOLECULAR CELL (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar et al.
CANCER DISCOVERY (2012)
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Nicolai J. Birkbak et al.
CANCER DISCOVERY (2012)
DNA repair dysregulation from cancer driver to therapeutic target
Nicola J. Curtin
NATURE REVIEWS CANCER (2012)
Double-Strand Break End Resection and Repair Pathway Choice
Lorraine S. Symington et al.
ANNUAL REVIEW OF GENETICS, VOL 45 (2011)
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors: Exploiting a Synthetic Lethal Strategy in the Clinic
Timothy A. Yap et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications
Sophie E. Polo et al.
GENES & DEVELOPMENT (2011)
Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins
Arti Yadav et al.
MOLECULAR CANCER THERAPEUTICS (2011)
PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
Stuart L. Rulten et al.
MOLECULAR CELL (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
The MRE11 complex: starting from the ends
Travis H. Stracker et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
Cecilia E. Strom et al.
NUCLEIC ACIDS RESEARCH (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway
Michael R. Lieber
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 79 (2010)
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Norman Chan et al.
CANCER RESEARCH (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
Tomasz Byrski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
The DNA Damage Response: Making It Safe to Play with Knives
Alberto Ciccia et al.
MOLECULAR CELL (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research
Susan L. Neuhausen et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
Helen E. Bryant et al.
EMBO JOURNAL (2009)
Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination
Isabelle Robert et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
Susan J. Ramus et al.
MOLECULAR ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer
Angela Chetrit et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
Single-strand break repair and genetic disease
Keith W. Caldecott
NATURE REVIEWS GENETICS (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites
Jean-Francois Haince et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Meta-analysis of BRCA1 and BRCA2 penetrance
Sining Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Minli Wang et al.
NUCLEIC ACIDS RESEARCH (2006)
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
K. Gudmundsdottir et al.
ONCOGENE (2006)
Poly(ADP-ribose):: novel functions for an old molecule
Valerie Schreiber et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs
RS Bindra et al.
CANCER RESEARCH (2005)
Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy
T Helleday et al.
CELL CYCLE (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD(+) into a nuclear signal
MY Kim et al.
GENES & DEVELOPMENT (2005)
Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing
M Malanga et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The 40 kDa carboxy-terminal domain of poly(ADP-ribose) polymerase-1 forms catalytically competent homo- and heterodimers in the absence of DNA
H Mendoza-Alvarez et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Nrf2 is a key transcription factor that regulates antioxidant defense in macrophages and epithelial cells: Protecting against the proinflammatory and oxidizing effects of diesel exhaust chemicals
N Li et al.
JOURNAL OF IMMUNOLOGY (2004)
Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells
RS Bindra et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
N Schultz et al.
NUCLEIC ACIDS RESEARCH (2003)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
A Antoniou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
V Schreiber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Physiology and pathophysiology of poly(ADP-ribosyl)ation
A Bürkle
BIOESSAYS (2001)
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
R Moslehi et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2000)
分享论文
